Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients.
It was previously shown that a tat mutant (tat22) where cysteine 22 is substituted by glycine behaves as a transdominant negative mutant in Jurkat T cells lytically or latently infected by HIV-1. In this study we demonstrate that tat22 controls HIV-1 replication in primary cells. This effect was observed both after in vitro infection of peripheral blood mononuclear cells (PBMCs) from normal donors and after reactivation of the latent infection in PBMCs from seropositive patients. The antiviral effect of tat22 was limited to conditions of low virus production. The use of tat22 may be promising for a gene therapy approach to AIDS during the asymptomatic phase of the disease allowing control of virus replication in infected cells and inhibition of virus spread to uninfected cells.
Rossi
C
C
Department of Experimental and Diagnostic Medicine, University of Ferrara, Italy.
Balboni
P G
PG
Betti
M
M
Marconi
P C
PC
Bozzini
R
R
Grossi
M P
MP
Barbanti-Brodano
G
G
Caputo
A
A
D015696:Gene Products, tat / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods*; D015658:HIV Infections / Q000276:immunology* / Q000628:therapy; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D009154:Mutation; D013601:T-Lymphocytes / Q000821:virology*; D014779:Virus Replication; D054322:tat Gene Products, Human Immunodeficiency Virus
D015696:Gene Products, tat; D054322:tat Gene Products, Human Immunodeficiency Virus